Contrast Media Shortage Resources

The COVID-19-related shutdown of a GE Healthcare plant in Shanghai has interrupted manufacture of iodinated contrast media used in many imaging exams. GE Healthcare’s and contrast media were added to the FDA drug shortage list on May 9. This shortage is forcing the delay of many non-emergency exams.

The 黑料网® offers the following resources to help practices continue to provide necessary care during this trying time. These resources are not intended to be — nor offered as — comprehensive medical guidelines. The 黑料网 will update this page as reliable information becomes available.

黑料网 Resources

黑料网 Advocacy In Action: FDA Approves Temporary Importation of Bracco Iomeprol Injection  - Added July 15

黑料网 Advocacy In Action: FDA Allows US Providers to Buy Bayer Foreign-Labeled Contrast Media - Added July 14

黑料网 and RBMA Ask Payers for Prior Authorization Flexibility Due to Contrast Media Shortage - Added May 26

黑料网 Works With Federal Government to Help Address Contrast Shortage Issues - Added May 24

黑料网 Statement on Contrast Media Shortage - Updated May 13
This statement offers some recommendations on how providers may address this emergency locally. The recommendations are not exhaustive or prescriptive. Providers and administrative leaders are encouraged to incorporate sound clinical judgment in all decisions affecting patient care.

黑料网 Appropriateness Criteria: Use AC Portal to search for alternative imaging studies for a given indication (that may not require contrast material) by clicking the “Explore by scenario” icon.

黑料网 Contrast Manual — APPENDIX A: Contrast Media Specifications Table

Peer-to-Peer Information (not official 黑料网 guidance)

J黑料网

AJR

Other Helpful Resources

  • FDA:
  • CDC:
  • ASHP:
  • JAMA: